Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 14/20 | 0.38 |
| ▸ | DRD3 | P35462 | 14/20 | 0.38 |
| ▸ | DRD2 | P14416 | 13/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | SMO | Q99835 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4839490 | 0.85 | HTR2A (0.47) | HTR1DHTR1BHTR2ADRD3DRD2 | |
| SCHEMBL4839745 | 0.84 | MCHR1 (0.46) | DRD2 | |
| SCHEMBL4833361 | 0.83 | TRPM8 (0.44) | HTR2ADRD3DRD2HSD11B1 | |
| SCHEMBL4839710 | 0.80 | HSD11B1 (0.38) | HTR1DHTR1BHSD11B1 | |
| SCHEMBL4836909 | 0.79 | NPSR1 (0.49) | HTR1DHTR1BHTR2ADRD3DRD2 | |
| SCHEMBL4830065 | 0.79 | NPSR1 (0.51) | HTR1DHTR1BHTR2ADRD3DRD2 | |
| SCHEMBL4839787 | 0.78 | HTR2A (0.47) | HTR2ADRD3DRD2 | |
| SCHEMBL4837162 | 0.77 | DRD2 (0.40) | HTR1DHTR1BHTR2ADRD3DRD2 | |
| SCHEMBL4839919 | 0.74 | CYP2C19 (0.44) | — | |
| SCHEMBL4837821 | 0.74 | HTR1D (0.37) | HTR1DHTR1BHTR2ADRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384957-B2 | 3,4-dihydro-1H-isoquinolin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2008-06-10 | — | — | US | claimed |
| US-20050070713-A1 | 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2005-03-31 | — | — | US | claimed |
| US-7384957-B2 | 3,4-dihydro-1H-isoquinolin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2008-06-10 | — | — | US | disclosed |
| US-20050070713-A1 | 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2005-03-31 | — | — | US | disclosed |
| EP-1458714-A1 | 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES | H. Lundbeck A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003051869-A1 | 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES | H. LUNDBECK A/S (DK) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070713-A1 | 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives | KCNJ2, KCNK2, KCNJ11 | HTR1D 1283/4885HTR1B 1045/4885HTR2A 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.